Edoxaban affects TRAP-dependent platelet aggregation.

Adult Aged Aged, 80 and over Atrial Fibrillation / complications Factor Xa Inhibitors / pharmacology Female Humans Male Middle Aged Platelet Aggregation / drug effects Prospective Studies Pyridines / pharmacology Stroke / etiology Thiazoles / pharmacology
Aggregation Doacs Edoxaban Platelet

Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
May 2020
Historique:
pubmed: 30 3 2020
medline: 12 2 2021
entrez: 30 3 2020
Statut: ppublish

Résumé

Edoxaban is an oral anticoagulant drug and a direct factor Xa inhibitor. However, it is still not fully understood if and how edoxaban impacts platelet function. This prospective study aimed to assess in vitro platelet function in patients with atrial fibrillation (AF) receiving edoxaban. It was a single centre study quantifying platelet aggregation in 20 patients treated with edoxaban by light transmission aggregometry. The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly lower 2 h after taking edoxaban compared to baseline value (44.7 ± 32.03% vs. 73.3 ± 25.55%; p < 0.0001). In addition, we did not find any significant difference in results between the patient groups.The TRAP-induced platelet aggregation is reduced in non-valvular AF patients receiving edoxaban.

Identifiants

DOI: 10.1007/s11239-020-02093-9 PMID: 32221807
pubmed: 32221807
doi: 10.1007/s11239-020-02093-9
pii: 10.1007/s11239-020-02093-9
doi:

Substances chimiques

Factor Xa Inhibitors 0
Pyridines 0
Thiazoles 0
edoxaban NDU3J18APO

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

578-583

Subventions

Organisme : Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
ID : VEGA 1/0187/17
Organisme : Agentúra na Podporu Výskumu a Vývoja
ID : APVV-17-0054

Références

J Thromb Haemost. 2003 Jul;1(7):1504-14
pubmed: 12871286
Curr Treat Options Cardiovasc Med. 2010 Jun;12(3):274-91
pubmed: 20842548
J Thromb Thrombolysis. 2016 Jan;41(1):32-67
pubmed: 26780738
Acta Biomater. 2018 Jun;73:228-235
pubmed: 29654993
Br J Haematol. 2011 Oct;155(1):30-44
pubmed: 21790527
J Cardiovasc Pharmacol Ther. 2014 Sep;19(5):409-16
pubmed: 24607764
J Thromb Thrombolysis. 2016 Jan;41(1):206-32
pubmed: 26780747
J Thromb Thrombolysis. 2015 Apr;39(3):288-94
pubmed: 25669624
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
Am Fam Physician. 2018 Apr 15;97(8):529-530
pubmed: 29671492
Nature. 1967 Dec 2;216(5118):857-8
pubmed: 6074962
Clin Appl Thromb Hemost. 2018 Sep;24(6):914-919
pubmed: 29050502
Clin Appl Thromb Hemost. 2018 Mar;24(2):268-272
pubmed: 28703014
J Thromb Haemost. 2015 Nov;13(11):1949-59
pubmed: 26386264
Drugs Today (Barc). 2019 Mar;55(3):197-214
pubmed: 30938374
Blood. 1991 Feb 15;77(4):770-9
pubmed: 1704263
Nature. 2000 Sep 14;407(6801):258-64
pubmed: 11001069
Blood. 2014 Sep 11;124(11):1705-14
pubmed: 24869936

Auteurs

Frantisek Nehaj (F)

First Department of Internal Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia.

Juraj Sokol (J)

Department of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia. juraj.sokol@me.com.
ORCID: 0000-0003-2786-0505

Jela Ivankova (J)

Department of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia.

Michal Mokan (M)

First Department of Internal Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia.

Marian Mokan (M)

Department of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia.

Jan Stasko (J)

Department of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Sujet âgé › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › États, signes et symptômes pathologiques › Processus pathologiques › Troubles du rythme cardiaque › Fibrillation auriculaire › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents hématologiques › Anticoagulants › Antithrombiniques › Inhibiteurs du facteur Xa › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiogiques du sang › Hémostase › Activation plaquettaire › Agrégation plaquettaire › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Maladies cardiovasculaires › Maladies vasculaires › Angiopathies intracrâniennes › Accident vasculaire cérébral › Edoxaban affects TRAP-dependent platelet aggregation.
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Thiazoles › Edoxaban affects TRAP-dependent platelet aggregation.